Current location:
Chinese researchers develop immunotherapeutic agent for colon cancer
Time:2024-05-21 19:30:43 Source:entertainmentViews(143)
TIANJIN, March 15 (Xinhua) -- Chinese researchers have developed a novel immunotherapeutic agent for treating colon cancer, according to a recent article in the academic journal ACS Nano. In animal experiments, the agent, upon successful entry into tumor cells, can enhance T cell effector function to kill tumor cells and suppress colon tumor growth, according to Lu Chunwan from the School of Life Sciences of Tianjin University, one of the authors of the article. The agent can enhance tumor immunogenicity and inhibit colon tumor growth, with no significant impact on normal cells, said Lu. Colon cancer, characterized by its long latency period and high mortality rate, poses a severe threat to human health. Among various therapies, immunotherapy is considered one of the most promising treatment directions, according to Lu.
(Editor:Fu Bo)
share to:
Previous:College baseball notebook: Conference tournaments to decide NCAA automatic bids and many at
Next:Cruise worker 'murders newborn son on board ship': Shocked co
Kind tips:The above content and pictures are compiled from the Internet and are for reference only. I hope they will be helpful to you! If there is any infringement, please contact us to delete it.!
You may also like
- Uber and Lyft say they'll stay in Minnesota after Legislature passes driver pay compromise
- Justice Thomas misses Supreme Court session with no explanation
- How major US stock indexes fared Monday, 4/15/2024
- Padres sign veteran infielder Donovan Solano to minor league deal
- Hollywood star Shia LaBeouf is spotted on the streets of Gavin and Stacey's hometown Barry
- Las Vegas lawyer and wife killed amid custody fight for children from prior marriage, family says
- China promotes human organ donation, transplantation
- Judge awards $23.5 million to undercover St. Louis officer beaten by colleagues during protest
- A warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue it